iNCOVACC

iNCOVACC will be the world’s first COVID-19 booster dose. It will give India more options to choose from when it comes to third doses or precautionary doses

Phase III trials (as a 2-dose regimen) were conducted for safety, immunogenicity in ~3100 subjects, in 14 trial sites across India.

Bharat Biotech’s Intranasal Vaccine receives both Primary series and Heterologous booster approval from from the Central Drugs Standard Control Organisation (CDSCO). This is first ever Intranasal Vaccine approved under restricted emergency use for 18+ for heterologous booster doses.. This vaccine was tested on 3100 candidates at 14 trial sites across India majorly for immunogenicity during […]